Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics. [electronic resource]
Producer: 20171005Description: 427-436 p. digitalISSN:- 1880-3989
- Administration, Oral
- Animals
- Chlorpromazine -- administration & dosage
- Cholestasis -- chemically induced
- Cholesterol -- biosynthesis
- Cyclosporine -- administration & dosage
- Diclofenac -- administration & dosage
- Dose-Response Relationship, Drug
- Flutamide -- administration & dosage
- Gene Expression
- Humans
- Imipramine -- administration & dosage
- Inflammation -- genetics
- Ketoconazole -- administration & dosage
- Liver
- Methyltestosterone -- administration & dosage
- Oxidative Stress -- genetics
- Rats
- Risk Assessment -- methods
- Sulindac -- administration & dosage
- Tamoxifen -- administration & dosage
- Toxicogenetics -- methods
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.